

# IMUGENE LIMITED

## APPENDIX 4D

### Half-year ended 31 December 2023



Name of entity: Imugene Limited  
 ABN: 99 009 179 551  
 Half-year ended: 31 December 2023  
 Previous period: 31 December 2022

#### Results for announcement to the market

\$

Revenue from ordinary activities	–	–%	To	–
Loss from ordinary activities after tax attributable to members	Up	295%	To	(68,714,834)
Net loss for the period attributable to members	Up	295%	To	(68,714,834)

#### Distributions

No dividends have been paid or declared by the Group for the current financial period. No dividends were paid for the previous financial period.

#### Explanation of results

Please refer to the review of operations and activities on pages 3 to 7 for explanation of the results.

This information should be read in conjunction with the 2023 annual report. Additional information supporting the Appendix 4D disclosure requirements can be found in the review of operations and activities, directors' report and the financial statements for the half-year ended 31 December 2023.

	31 December 2023 Cents	31 December 2022 Cents
<b>Net tangible assets per security</b>		
Net tangible asset backing (per security)	2.18	2.74

The calculation of net tangible assets excludes right-of-use assets arising from AASB 16 Leases.

#### Controlled entities

There have been no changes in controlled entities during the half-year ended 31 December 2023.  
 Other information required by Listing Rule 4.2A

- |    |   |     |
|----|---|-----|
| a. | Details of individual and total dividends or distributions and dividend or distribution payments: | N/A |
| b. | Details of any dividend or distribution reinvestment plans:                                       | N/A |
| c. | Details of associates and joint venture entities:   | N/A |
| d. | Other information   | N/A |

#### Interim review

The financial statements have been reviewed by the Group's independent auditor without any modified opinion, disclaimer or emphasis of matter.



**IMUGENE**

Developing Cancer  
Immunotherapies

**ASX:IMU**

# HALF YEAR REPORT 2023

Imugene Limited  
ABN 99 009 179 551

## CONTENTS

<b>Review of Operations &amp; Activities</b>	<b>3</b>
<b>Director's Report</b>	<b>8</b>
<b>Financial Statements</b>	<b>11</b>

# REVIEW OF OPERATIONS & ACTIVITIES

Imugene Limited is pleased to announce its financial results for the half year ended 31 December 2023.

## FINANCIAL REVIEW

Imugene Limited and its subsidiaries (the Group) reported a loss for the period ended 31 December 2023 of \$68,714,834 (31 December 2022: \$17,392,700). This increased loss compared to the comparative period is largely driven by the increase in clinical trial and research activities undertaken by the Group.

Following a successful capital raising through a placement and Share Purchase Plan, the Group's net assets increased to \$194,831,156 (30 June 2023: \$189,626,002). As at 31 December 2023, the Group had cash reserves of \$139,392,025 (30 June 2023: \$153,150,662).

On 16 August 2023, the Group announced that it has entered into an agreement with Precision Biosciences, Inc. (NASDAQ GS: DTIL) of North Carolina, USA, to acquire a worldwide exclusive license to Precision's azer-cel allogeneic CD19 CAR T cell therapy program. Given the nature of the acquisition, it has been concluded that this is an asset acquisition, and the assets acquired included property, plant and equipment, intangible assets, other financial liabilities and other current assets totalling US\$21,300,000.

## OPERATING REVIEW

### Key highlights

- Acquired exclusive license for azer-cel CD19 CAR T cell therapy
- Commenced Phase 1b clinical trial of azer-cel in auto-CAR T failures with Diffused Large B-Cell lymphoma.
- Positive early data for VAXINIA Phase 1 MAST trial.
- VAXINIA granted Food and Drug Administration (FDA) Fast Track Designation for bile tract cancer.
- Continued progression through higher dose cohorts in VAXINIA MAST trial.
- Phase 1 clinical trial underway for CD19 oncolytic virotherapy onCARlytics.
- NeoPOLEM Phase 2 clinical trial for PD1-Vaxx to start in UK & Australia.
- Strategic collaboration with NeolmmuneTech for azer-cel enhancement.
- Renovox collaboration signed to improve CF33 virotherapy delivery.
- Imugene and its technologies featured at SITC, JP Morgan and ESMO.
- Key new appointments to senior management team.
- \$35m Placement & \$18.2m Share Purchase Plan (SPP) completed.

### Azer-cel acquisition and commencement of Phase 1b clinical trial

In August, Imugene announced the acquisition of a global exclusive license for the azer-cel allogeneic CD19 CAR T cell therapy program from Precision Biosciences, Inc. This key acquisition encompasses an extensive clinical data set with azer-cel demonstrating robust efficacy, especially in patients with Diffuse Large B Cell Lymphoma (DLBCL) post-auto CAR T therapy relapse. The therapy has shown strong potential for those who unfortunately progress following treatment with autologous CD19 CAR T cell therapies, with azer-cel having a pathway to start a registrational study and become the first approved allogeneic (allo) CAR T cell therapy for cancer.

In an ongoing multi-centre Phase 1 clinical trial that includes 84 patients with non-Hodgkin's lymphoma (NHL) and acute lymphocytic leukemia, azer-cel demonstrated clinically meaningful activity with an acceptable safety profile. Notably, the azer-cel data were especially strong in patients with DLBCL who had relapsed following auto CAR T therapy. Azer-cel achieved 83% Overall Response Rate, 61% Complete Response Rate with 55% durable response greater than or equal to six months in this difficult to treat auto CAR T relapse setting (n=18).

### **Azer-cel acquisition and commencement of Phase 1b clinical trial (continued)**

To facilitate this acquisition, Imugene agreed to a series of financial commitments, including an upfront cash payment, deferred considerations, and potential milestone payments. The Group has also assumed the lease of a GMP manufacturing facility in North Carolina and has integrated a team of approximately 50 cell therapy and manufacturing specialists. The FDA has provided positive feedback on the azer-cel manufacturing process, which is set to be used in pivotal clinical trials and potentially for commercial production. Furthermore, the transfer of the Investigational New Drug Application (IND) for azer-cel from Precision Biosciences to Imugene has been officially approved by the FDA. Imugene is also optimistic about the highly complementary nature of azer-cel to its onCARlytics platform.

Following the acquisition, Imugene announced the commencement of the Phase 1b clinical trial of azer-cel with the dosing of the first patient. This trial, which includes patients suffering from NHL, builds upon the promising outcomes of the Phase 1 study. Conducted across leading US centres, the Phase 1 study exhibited strong safety and efficacy signals from azer-cel. The current Phase 1b trial at multiple U.S. sites, aims to extend these results, particularly in DLBCL patients who have relapsed after CAR T therapy. The success of this trial is anticipated to lay the groundwork for a registrational study in 2024, setting the stage for azer-cel to potentially become the inaugural approved allogeneic CAR T cell therapy for cancer.

### **Major developments and positive early signals for VAXINIA**

In the past six months, Imugene has achieved significant milestones in the clinical development of VAXINIA (CF33-hNIS). Early data was received for the Phase 1 MAST (Metastatic Advanced Solid Tumours) trial of VAXINIA, showing promising results.

Of the 34 heavily pre-treated patients administered VAXINIA, responses included a Complete Response in a patient with advanced bile tract cancer and a Partial Response in a patient with advanced melanoma. The trial also reported 16 instances of Stable Disease across various cancer types. Importantly, seven patients with gastrointestinal cancers who received VAXINIA alone during dose escalation achieved a disease control rate of 86%.

VAXINIA's potential was further recognized with the Fast Track Designation granted by the US FDA for the treatment of bile tract cancer, underscoring the oncolytic virus's capacity to address significant unmet medical needs. This designation is instrumental in facilitating an accelerated review process, potentially hastening VAXINIA's regulatory journey. In response to positive early signals, particularly in gastrointestinal cancer patients, Imugene has outlined plans to extend the trial to include an additional 10 to 20 patients with bile duct cancers, a group that typically faces limited treatment options.

The early outcomes highlight VAXINIA's potential as a multi-faceted treatment in oncology. Following these promising results, the MAST trial continues to progress, with the expansion into new cohorts for both monotherapy and combination therapy studies. These cohorts form part of a comprehensive dose escalation study designed to assess the safety and efficacy of VAXINIA, initially developed by the City of Hope.

### **onCARlytics Phase 1 clinical trial underway**

In October, the Group announced the commencement of its Phase 1 clinical trial for CD19 oncolytic virotherapy drug candidate, onCARlytics. The first patient in the trial, designed to treat solid tumours, was dosed at City of Hope's NCI-Designated Comprehensive Cancer Center in Duarte, California, USA.

The first-in-class Phase 1 clinical trial of onCARlytics (CF33-CD19), known as OASIS, is being conducted in patients with solid tumours and is titled "A Phase I Dose Escalation and Dose Expansion Safety and Tolerability Study of onCARlytics (CF33-CD19) Administered Intravenously or Intratumorally in Combination with Blinatumomab in Adults with Advanced or Metastatic Solid Tumours".

The trial seeks to evaluate the safety and efficacy of two routes of administration – intratumoural injection and intravenous infusion – either alone or in combination with blinatumomab (Blinicyto®). onCARlytics has the potential to target and eradicate solid tumours that otherwise cannot be treated with Blinicyto® therapy alone.

The OASIS trial is being conducted at multiple US sites and is a world-first for clinical trial initiation of a CD19 oncolytic virus combination with a CD19 directed therapies.

### **PD1-Vaxx Phase 2 neoPOLEM clinical trial to open in UK & Australia; European and Japanese patents granted**

In December, Imugene announced the commencement of a Phase 2 neoPOLEM clinical trial for PD1-Vaxx in patients with colorectal cancer (CRC) in the United Kingdom and Australia. This trial, set to begin in 2024, will evaluate the efficacy of PD1-Vaxx in combination with standard-of-care chemotherapy for CRC.

Approximately 44 patients will be enrolled across approximately 10 sites – 6 in Australia and 4 in the UK. The trial is an Investigator Sponsored Study and will be conducted by Cancer Research UK Southampton Clinical Trials Unit in collaboration with Royal Surrey Hospital NHS Foundation Trust and The Australasian Gastro-Intestinal Trials Group. The primary objective of the study is to determine major pathological response rates, a measure of tumour size reduction post-treatment with PD1-Vaxx before surgery.

The Group also announced it will be granted patents in Europe and Japan for PD1-Vaxx. Corresponding applications are pending in Canada, China, Hong Kong, India, South Korea, Brazil and Australia.

### **Strategic research collaboration with NeolImmuneTech**

In December the Group announced a strategic collaboration with NeolImmuneTech (NIT) to enhance cancer treatments. This collaboration will focus on evaluating the potential of NIT's immune cell amplifier NT-I7 to improve the efficacy of Imugene's azer-cel technology. The partnership aims to explore:

- The ability of NIT's NT-I7 to increase the number of azer-cel allogeneic CAR T cells per batch during manufacturing. This could potentially enhance the scalability and accessibility of this novel therapy.
- The potential for the combination to increase the number and cancer-fighting properties of patients' own T cells during treatment with azer-cel.

The collaboration is set to continue for two years, with research activities being conducted exclusively in the United States.

Both parties retain intellectual property rights to their respective technologies, and any new intellectual property generated from this collaboration will be discussed for joint filing and prosecution.

### **RenovoRx CF33 virotherapy delivery collaboration**

Imugene and RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company specializing in targeted combination therapies, announced a strategic research collaboration aiming to enhance the delivery of Imugene's oncolytic virus therapy using RenovoRx's TAMP (Trans-Arterial Micro-Perfusion) therapy platform for treating difficult to-access tumours.

The collaboration is set to explore the potential benefits of administering Imugene's CF33 oncolytic virus with RenovoRx's TAMP platform for tumours such as pancreatic and liver cancers. Traditional methods may be limited by dense fibrous tissue and inadequate blood supply to these tumours.

### **CF33 featured at SITC**

Imugene's CF33 Oncolytic Virus technology was highlighted at the Annual Meeting for the Society for Immunotherapy of Cancer (SITC) in San Diego, US. SITC is a prestigious event showcasing advanced research presentations in immunotherapy. The CF33 technology was presented through a Trial-in-Progress Poster: A Phase I Safety and Tolerability Study of VAXINIA (CF33-hNIS) in Adults with Metastatic or Advanced Solid Tumors.

### **HER-Vaxx and CHECKVacc featured at ESMO Congress**

In October, Imugene announced presentations of its B cell immunotherapy HER-Vaxx and CF33 oncolytic virotherapy CHECKVacc at the ESMO Congress in Madrid. The European Society for Medical Oncology (ESMO) Congress is the most influential oncology platform for clinicians, researchers, patient advocates, journalists, and healthcare industry representatives from all over the world.

### **Participation at JP Morgan Healthcare Conference**

Imugene announced its participation at the 42nd Annual J.P. Morgan Healthcare Conference, which took place subsequent to the end of the reporting period. At the conference, CEO & MD Leslie Chong showcased Imugene's technology to a varied audience of industry participants and investors who travel from around the world for what is considered a marquee event on the biotechnology calendar.

### Key appointments to senior management team

#### *Dr Bradley Glover appointed Chief Operating Officer*

In August 2023, Imugene announced the appointment of Dr Bradley Glover as its Chief Operating Officer. Dr Glover has extensive experience across various fields, including cell therapy, biopharmaceuticals, and diagnostics. He has a proven track record in strategic collaborations, acquisitions, licensing, and meaningful academic contributions in biochemistry and genetics.

#### *Dr Paul Woodard appointed Chief Medical Officer*

Dr Paul Woodard joined Imugene as Chief Medical Officer during the half year. Before joining Imugene, Dr Woodard held roles in various drug development projects concerning solid tumours, hematologic malignancies, and non-malignant hematologic disorders. He was previously the Senior Vice President and Chief Medical Officer at Immune-Onc Therapeutics, where he was instrumental in clinical oversight, initiating Phase 1 clinical trials, and submitting four novel INDs.

#### *Dr John Byon appointed Senior Vice President of Clinical Development*

Imugene also announced the appointment of Dr John Byon as Senior Vice President of Clinical Development during the half year. Dr Byon has a distinguished history in developing novel therapeutics for cancer patients, holding leadership roles in major biopharmaceutical companies.

### **\$35m Placement and \$18.2m SPP**

Imugene secured firm commitments for a \$35 million placement with the issue of approximately 416.7m new shares at \$0.084 per share in conjunction with the azer-cel acquisition. This Placement gained robust support from company directors and management, who committed \$840,000.

The Group also completed a SPP, raising an additional \$18.2 million. Funds raised are going towards payments associated with the azer-cel license agreement with Precision Biosciences Inc., including advancing the Phase 1b clinical trial for the azer-cel Allogeneic CD19 Car-T technology.

## EVENTS SINCE THE END OF THE HALF YEAR

### Phase 1 CF33-hNIS (VAXINIA) MAST trial doses first patients in higher dose cohorts

In January 2024 the Group announced that the MAST trial has continued to progress with the first patients dosed in each monotherapy arm (intratumoral and intravenous) of cohort 5 of the Phase 1 study. The combination study, where VAXINIA is administered with pembrolizumab, also continues to actively enrol new patients with 13 patients enrolled to date, in addition to the 24 patients dosed in the monotherapy arms, with no safety issues observed.

In January the Group also provided an update on its Phase 1 MAST trial and the positive early data originally announced in November 2023. The latest data noted that 38 patients had been treated, showing that the treatments are safe and tolerable. Notably, one patient with biliary tract cancer achieved a complete response and has been in remission for over 430 days. Additionally, the trial demonstrated a 47% reduction in tumor burden in intratumorally treated lesions, with some lesions being completely eradicated. Stable disease was observed in 53% of patients in intravenous cohorts. As noted above, the trial plans to expand to include 10-20 patients with biliary tract cancers, which are generally challenging to treat.

### VAXINIA findings presented at ASCO GI Cancers Symposium

Imugene Limited presented their findings on the CF33-hNIS (VAXINIA) virus as a monotherapy for gastrointestinal malignancies at the ASCO GI Cancers Symposium. Preliminary data from the trial showed promising anti-tumor activity, including a complete immunological response in a patient with cholangiocarcinoma who remained in remission after one year. The therapy may be a viable option for gastrointestinal cancers, especially biliary tract cancer, and shows potential in immunomodulation to promote anti-tumor immunity.

For and on behalf of the Group,



Leslie Chong

CEO and Managing Director



# DIRECTOR'S REPORT

## Directors

The following persons were directors of Imugene Limited during the half-year and up to the date of this report:

- Mr Paul Hopper, Executive Chairman
- Ms Leslie Chong, Chief Executive Officer and Managing Director
- Dr Lesley Russell, MD, Non-Executive Director
- Dr Jens Eckstein, PhD, Non-Executive Director
- Dr Jakob Dupont, MD, Non-Executive Director
- Ms Kim Drapkin, Non-Executive Director

## Review of operations and activities

Information on the financials and operations of the Group and its business strategies and prospects is set out in the review of operations and activities on pages 3 to 7 of this half year report.

## Significant changes in the state of affairs

In August 2023, Imugene Limited completed a placement to raise \$35,000,000 by issuing 416,700,000 shares at \$0.084 per share.

In August 2023, the Group also entered into an agreement with Precision Biosciences, Inc. (NASDAQ GS: DTIL) of North Carolina, USA, to acquire a worldwide exclusive license to the azer-cel allogeneic CD19 CAR T cell therapy program, expanding its footprint in the USA. The Group has also assumed the lease of a GMP manufacturing facility in North Carolina and has integrated a team of approximately 50 cell therapy and manufacturing specialists.

In September 2023, shares of 325,000,000 were issued to partaking investors in a Share Purchase Plan. The shares were issued at \$0.056 per share and for every new share subscribed a free - attaching option was given. The free -attaching options have an exercise price of \$0.118.

In September 2023, Imugene Limited announce the FDA has transferred the IND Application for its allogeneic CD19 CAR T azer-cel from Precision Biosciences Inc. (NASDAQ GS: DTIL) to Imugene, following the exclusive worldwide license acquired in August.

In the opinion of the directors there were no other significant changes in the state of affairs of the Group that occurred during the period.

## Matters subsequent to the end of the period

No matter or circumstance has arisen since 31 December 2023 that has significantly affected, or may significantly affect:

- (a) the Group's operations in future financial periods, or
- (b) the results of those operations in future financial periods, or
- (c) the Group's state of affairs in future financial periods.

### **Auditor's independence declaration**

A copy of the auditor's independence declaration as required under section 307C of the Corporations Act 2001 is set out on page 10.

### **Rounding of amounts**

The Group is of a kind referred to in ASIC Legislative Instrument 2016/191, relating to the 'rounding off' of amounts in the directors' report and financial report. Amounts in the directors' report and financial report have been rounded off to the nearest dollar in accordance with the instrument.

This report is made in accordance with a resolution of directors.



Mr Paul Hopper  
Executive Chairman  
Sydney  
29 February 2024

---

**Grant Thornton Audit Pty Ltd**

Level 22 Tower 5  
Collins Square  
727 Collins Street  
Melbourne VIC 3008  
GPO Box 4736  
Melbourne VIC 3001  
T +61 3 8320 2222

## Auditor's Independence Declaration

### To the Directors of Imugene Limited

In accordance with the requirements of section 307C of the *Corporations Act 2001*, as lead auditor for the review of Imugene Limited for the half-year ended 31 December 2023. I declare that, to the best of my knowledge and belief, there have been:

- a no contraventions of the auditor independence requirements of the *Corporations Act 2001* in relation to the review; and
- b no contraventions of any applicable code of professional conduct in relation to the review.



Grant Thornton Audit Pty Ltd  
Chartered Accountants



M A Cunningham  
Partner – Audit & Assurance

Melbourne, 29 February 2024

**[www.grantthornton.com.au](http://www.grantthornton.com.au)**  
**ACN-130 913 594**

---

Grant Thornton Audit Pty Ltd ACN 130 913 594 a subsidiary or related entity of Grant Thornton Australia Limited ABN 41 127 556 389 ACN 127 556 389. 'Grant Thornton' refers to the brand under which the Grant Thornton member firms provide assurance, tax and advisory services to their clients and/or refers to one or more member firms, as the context requires. Grant Thornton Australia Limited is a member firm of Grant Thornton International Ltd (GTIL). GTIL and the member firms are not a worldwide partnership. GTIL and each member firm is a separate legal entity. Services are delivered by the member firms. GTIL does not provide services to clients. GTIL and its member firms are not agents of, and do not obligate one another and are not liable for one another's acts or omissions. In the Australian context only, the use of the term 'Grant Thornton' may refer to Grant Thornton Australia Limited ABN 41 127 556 389 ACN 127 556 389 and its Australian subsidiaries and related entities. Liability limited by a scheme approved under Professional Standards Legislation.



**IMUGENE**

Developing Cancer Immunotherapies

For personal use only

Half Year Report 2023

# FINANCIAL STATEMENTS

# CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

For the half-year ended 31 December 2023

	Notes	31 December 2023 \$	31 December 2022 \$
Other income	2(a)	8,068,065	4,813,301
Other gains/(losses)		154,225	(779,249)
General and administrative expenses		(34,557,167)	(9,255,098)
Research and development expenses		(44,675,921)	(12,650,912)
<b>Operating loss</b>		<b>(71,010,798)</b>	<b>(17,871,958)</b>
Finance income		2,561,371	493,659
Finance expenses		(265,407)	(14,401)
<b>Finance income – net</b>		<b>2,295,964</b>	<b>479,258</b>
<b>Loss before income tax</b>		<b>(68,714,834)</b>	<b>(17,392,700)</b>
Income tax expense		-	-
<b>Loss for the period</b>		<b>(68,714,834)</b>	<b>(17,392,700)</b>
<b>Other comprehensive income</b>			
<i>Items that may be reclassified to profit or loss:</i>			
Exchange differences on translation of foreign operations		1,007,692	12,307
<b>Total comprehensive loss for the period</b>		<b>(67,707,142)</b>	<b>(17,380,393)</b>
<b>Loss per share for loss attributable to the ordinary equity holders of the Group:</b>		<b>Cents</b>	<b>Cents</b>
Basic and diluted loss per share		(1.00)	(0.28)

The above consolidated statement of profit or loss and other comprehensive income should be read in conjunction with the accompanying notes.

## CONSOLIDATED STATEMENT OF FINANCIAL POSITION

As at 31 December 2023

	Notes	31 December 2023 \$	30 June 2023 \$
<b>Assets</b>			
<i>Current assets</i>			
Cash and cash equivalents		139,392,025	153,150,662
Trade and other receivables	3(a)	20,395,854	12,105,294
Other current assets		7,908,318	401,566
<b>Total current assets</b>		<b>167,696,197</b>	<b>165,657,522</b>
<i>Non-current assets</i>			
Other financial assets at amortised cost		217,564	217,564
Property, plant and equipment		23,276,400	682,973
Intangible assets	4	38,296,088	30,485,563
Other assets		936,314	19,309
<b>Total non-current assets</b>		<b>62,726,366</b>	<b>31,405,409</b>
<b>Total assets</b>		<b>230,422,563</b>	<b>197,062,931</b>
<b>Liabilities</b>			
<i>Current liabilities</i>			
Trade and other payables	3(b)	4,757,840	3,498,286
Other financial liabilities	3(c)	18,264,077	1,923,077
Employee benefit obligations		3,926,599	471,528
Other current liabilities		2,312,197	191,057
<b>Total current liabilities</b>		<b>29,260,713</b>	<b>6,083,948</b>
<i>Non-current liabilities</i>			
Other financial liabilities	3(c)	1,998,715	985,450
Employee benefit obligations		153,165	5,116
Other non-current liabilities		4,178,814	362,415
<b>Total non-current liabilities</b>		<b>6,330,694</b>	<b>1,352,981</b>
<b>Total liabilities</b>		<b>35,591,407</b>	<b>7,436,929</b>
<b>Net assets</b>		<b>194,831,156</b>	<b>189,626,002</b>
<b>Equity</b>			
Issued capital	5(a)	365,357,188	314,401,877
Other equity	5(c)	4,744,355	4,744,355
Other reserves	5(b)	34,880,453	11,915,776
Accumulated losses		(210,150,840)	(141,436,006)
<b>Total equity</b>		<b>194,831,156</b>	<b>189,626,002</b>

The above consolidated statement of financial position should be read in conjunction with the accompanying notes.

## CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

For the half-year ended 31 December 2023

	Notes	Share capital \$	Other equity \$	Other reserves \$	Accumulated losses \$	Total equity \$
<b>Balance at 1 July 2022</b>		230,788,745	4,744,355	6,692,760	(103,521,116)	138,704,744
Loss for the period		-	-	-	(17,392,700)	(17,392,700)
Other comprehensive loss		-	-	12,307	-	12,307
<b>Total comprehensive loss for the period</b>		<b>230,788,745</b>	<b>4,744,355</b>	<b>6,705,067</b>	<b>(120,913,816)</b>	<b>121,324,351</b>
<b>Transactions with owners in their capacity as owners:</b>						
Contributions of equity, net of transaction costs and tax	5(a)	74,958,079	-	-	-	74,958,079
Forfeiture of options	5(b)	-	-	(56,203)	-	(56,203)
Equity-settled payments	5(b)	-	-	30,695	-	30,695
Repayment of loaned shares to KMP	5(a)	22,168	-	-	-	22,168
Options exercised	5(b)	9,672,511	-	(1,257,000)	-	8,415,511
Options issued/expensed	5(b)	-	-	2,707,832	-	2,707,832
		84,652,758	-	1,425,324	-	86,078,082
<b>Balance at 31 December 2022</b>		<b>315,441,503</b>	<b>4,744,355</b>	<b>8,130,391</b>	<b>(120,913,816)</b>	<b>207,402,433</b>
<b>Balance at 1 July 2023</b>		314,401,877	4,744,355	11,915,776	(141,436,006)	189,626,002
Loss for the period		-	-	-	(68,714,834)	(68,714,834)
Other comprehensive income		-	-	1,007,692	-	1,007,692
<b>Total comprehensive loss for the period</b>		<b>314,401,877</b>	<b>4,744,355</b>	<b>12,923,468</b>	<b>(210,150,840)</b>	<b>121,918,860</b>
<b>Transactions with owners in their capacity as owners:</b>						
Contributions of equity, net of transaction costs and tax	5(a)	50,470,085	-	-	-	50,470,085
Forfeiture of options	5(b)	-	-	(319,550)	-	(319,550)
Convertible notes issued	5(b)	-	-	19,090,797	-	19,090,797
Options exercised	5(b)	485,226	-	1,178,002	-	1,663,228
Options issued/expensed	5(b)	-	-	2,007,736	-	2,007,736
		50,955,311	-	21,956,985	-	72,912,296
<b>Balance at 31 December 2023</b>		<b>365,357,188</b>	<b>4,744,355</b>	<b>34,880,453</b>	<b>(210,150,840)</b>	<b>194,831,156</b>

The above consolidated statement of changes in equity should be read in conjunction with the accompanying notes.

## CONSOLIDATED STATEMENT OF CASH FLOWS

For the half-year ended 31 December 2023

	Notes	31 December 2023 \$	31 December 2022 \$
<b>Cash flows from operating activities</b>			
Payments to suppliers and employees (inclusive of GST)		(50,872,947)	(21,093,552)
<b>Net cash outflow from operating activities</b>		(50,872,947)	(21,093,552)
<b>Cash flows from investing activities</b>			
Payments for property, plant and equipment		(7,722,007)	-
Payments for intangible assets		(3,775,410)	-
Payments for other assets		(4,894,991)	-
Interest received		2,451,703	493,659
<b>Net cash (outflow)/inflow from investing activities</b>		(13,940,705)	493,659
<b>Cash flows from financing activities</b>			
Proceeds from issues of shares	5(a)	53,205,482	88,415,493
Share issue transaction costs		(2,735,397)	(5,041,921)
Principal elements of lease payments		(146,896)	(58,169)
Interest paid		-	(14,401)
<b>Net cash inflow from financing activities</b>		50,323,189	83,301,002
<b>Net (decrease)/increase in cash and cash equivalents</b>		(14,490,463)	62,701,109
Cash and cash equivalents at the beginning of the financial year		153,150,662	99,887,725
Effects of exchange rate changes on cash and cash equivalents		731,826	(680,826)
<b>Cash and cash equivalents at end of period</b>		139,392,025	161,908,008

The above consolidated statement of cash flows should be read in conjunction with the accompanying notes.

At 31 December 2023, a variance exists between the above statement of cash flows and the 31 December 2023 Appendix 4C. \$2.3m has been allocated to payments to suppliers in the above statement of cash flows from payments to acquire assets. \$2.2m has been allocated to share issue transaction costs from proceeds from issue of shares.



# NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

## 1 Segment information

Management has determined, based on the reports reviewed by the chief operating decision maker that are used to make strategic decisions, that the Group has one reportable segment being the research, development and commercialisation of health technologies. The segment details are therefore fully reflected in the body of the financial report.

## 2 Profit and loss information

### (a) Other income

Loss before income tax includes the following specific items:

	Consolidated entity	
	31 December 2023 \$	31 December 2022 \$
<b>Other income</b>		
Research and development tax incentive (i)	8,062,065	4,789,201
Other items	6,000	24,100
	<u>8,068,065</u>	<u>4,813,301</u>

#### (i) Research and development tax incentive

At 31 December 2023 the Group accrued \$8,062,065 (2022: \$4,789,201) in relation to the research and development spend for the current period.

## 3 Financial assets and financial liabilities

### (a) Trade and other receivables

	31 December 2023			30 June 2023		
	Current \$	Non- current \$	Total \$	Current \$	Non- current \$	Total \$
Accrued receivables (i)	20,102,421	-	20,102,421	11,930,688	-	11,930,688
Other receivables (ii)	293,433	-	293,433	174,606	-	174,606
	<u>20,395,854</u>	<u>-</u>	<u>20,395,854</u>	<u>12,105,294</u>	<u>-</u>	<u>12,105,294</u>

#### (i) Accrued receivables

Accrued receivables comprise \$19,803,592 from the Australian Taxation Office in relation to the R&D tax incentive (June 2023: \$11,741,527) and \$298,828 interest income from deposits at call (June 2023: \$189,160).

#### (ii) Fair value of other receivables

Due to the short-term nature of the other receivables, their carrying amount is considered to be a reasonable approximation of their fair value.

**3 Financial assets and financial liabilities (continued)****(b) Trade and other payables**

	Consolidated entity					
	31 December 2023			30 June 2023		
	Current	Non-current	Total	Current	Non-current	Total
	\$	\$	\$	\$	\$	\$
Trade payables	3,627,142	-	3,627,142	2,341,038	-	2,341,038
Accrued expenses	722,103	-	722,103	1,134,515	-	1,134,515
Other payables	408,595	-	408,595	22,733	-	22,733
	<b>4,757,840</b>	<b>-</b>	<b>4,757,840</b>	<b>3,498,286</b>	<b>-</b>	<b>3,498,286</b>

Trade payables are unsecured and are usually paid within 30 days of recognition.

The carrying amounts of trade and other payables are considered to be a reasonable approximation of their fair values, due to their short-term nature.

**(c) Other financial liabilities**

	Consolidated entity					
	31 December 2023			30 June 2023		
	Current	Non-current	Total	Current	Non-current	Total
	\$	\$	\$	\$	\$	\$
HER- Vaxx contingent consideration	-	985,450	985,450	-	985,450	985,450
CF33 contingent consideration	219,298	566,110	785,408	339,367	-	339,367
CD19 contingent consideration	1,766,432	268,801	2,035,233	1,583,710	-	1,583,710
Azer-cel contingent consideration	15,813,463	-	15,813,463	-	-	-
PD-1 and Non PD-1 contingent consideration	464,884	178,354	643,238	-	-	-
	<b>18,264,077</b>	<b>1,998,715</b>	<b>20,262,792</b>	<b>1,923,077</b>	<b>985,450</b>	<b>2,908,527</b>

**(i) Contingent consideration**

The fair value of contingent consideration relating to the acquisition of licences is estimated using a present value technique which discounts management's estimate of the probability that the milestone will be achieved. The discount rate used in the current period was 7.91% (June 2023: 4.52%).

**(d) Recognised fair value measurements****(i) Fair value hierarchy**

The following table provides the fair values of the Group's financial instruments measured and recognised on a recurring basis after initial recognition and their categorisation within the fair value hierarchy. To provide an indication about the reliability of the inputs used in determining fair value, the Group has classified its financial instruments into the three levels prescribed under the accounting standards. An explanation of each level follows underneath the table.

**3 Financial assets and financial liabilities (continued)****(b) Recognised fair value measurements (continued)**

<i>Recurring fair value measurements</i>		Level 1	Level 2	Level 3	Total
At 31 December 2023	Notes	\$	\$	\$	\$
Financial liabilities					
Expected future royalties payable					
HER-Vaxx contingent consideration	3(c)	-	-	985,450	985,450
CF33 contingent consideration	3(c)	-	-	785,408	785,408
CD19 contingent consideration	3(c)	-	-	2,035,233	2,035,233
Azer-cel contingent consideration	3(c)	-	-	15,813,463	15,813,463
PD-1 and Non PD-1 contingent consideration	3(c)	-	-	643,238	643,238
<b>Total financial liabilities</b>		-	-	20,262,792	20,262,792

<i>Recurring fair value measurements</i>		Level 1	Level 2	Level 3	Total
At 30 June 2023	Notes	\$	\$	\$	\$
Financial liabilities					
Expected future royalties payable					
HER-Vaxx contingent consideration	3(c)	-	-	985,450	985,450
CF33 contingent consideration	3(c)	-	-	339,367	339,367
CD19 contingent consideration	3(c)	-	-	1,583,710	1,583,710
<b>Total financial liabilities</b>		-	-	2,908,527	2,908,527

There were no transfers between levels of the hierarchy for recurring fair value measurements during the half year ended 31 December 2023.

**Level 1:** The fair value of financial instruments traded in active markets (such as publicly traded derivatives and equity securities) is based on quoted market prices at the end of the reporting period. The quoted market price used for financial assets held by the Group is the current bid price. These instruments are included in level 1.

**Level 2:** The fair value of financial instruments that are not traded in an active market (for example, over-the-counter derivatives) is determined using valuation techniques which maximise the use of observable market data and rely as little as possible on entity-specific estimates. If all significant inputs required to fair value an instrument are observable, the instrument is included in level 2.

**Level 3:** If one or more of the significant inputs is not based on observable market data, the instrument is included in level 3. This is the case for unlisted equity securities.

**4 Intangible assets**

	HER-Vaxx	PD1-Vaxx	Non PD1-Vaxx	CF33	CD19	Azer-cel	Total
	\$	\$	\$	\$	\$	\$	\$
<b>Half-year ended 31 December 2023</b>							
Opening net book amount	5,347,781	107,289	255,012	19,303,867	5,471,615	-	30,485,563
Additions	-	-	-	-	-	9,669,125	9,669,125
Amortisation charge	(210,569)	(3,934)	(12,052)	(689,157)	(195,301)	(747,587)	(1,858,600)
<b>Closing net book amount</b>	<b>5,137,212</b>	<b>103,355</b>	<b>242,960</b>	<b>18,614,710</b>	<b>5,276,314</b>	<b>8,921,538</b>	<b>38,296,088</b>

The Group's accounting policies and approach to assessing for indications of impairment are followed consistently in the interim financial statements as compared with the most recent annual financial statements.

**5 Equity**

	31 December 2023	31 December 2023	30 June 2023	30 June 2023
	No.	\$	No.	\$
Fully paid	7,169,086,938	365,357,188	6,423,039,111	314,401,877

**(a) Share capital***(i) Movements in ordinary shares*

Details	Number of shares	Total \$
Balance at 1 July 2023	6,423,039,111	314,401,877
Placement of ordinary shares	741,935,748	53,205,482
Issue on the exercise of listed options	4,112,079	485,226
Less: Transaction costs arising on share issues	-	(2,735,397)
<b>Balance at 31 December 2023</b>	<b>7,169,086,938</b>	<b>365,357,188</b>

*(ii) Rights of each type of share*

Ordinary shares entitle the holder to participate in dividends and the proceeds on winding up of the Group in proportion to the number of shares held. On a show of hands every holder of ordinary shares present at a meeting or by proxy, is entitled to one vote. Upon a poll every holder is entitled to one vote per share held. The ordinary shares have no par value.

**(b) Other reserves**

The following table shows a breakdown of the balance sheet line item other reserves and the movements in these reserves during the period. A description of the nature and purpose of each reserve is provided below the table.

Consolidated entity	Share- based payments \$	Foreign currency translation \$	Total other reserves \$
At 1 July 2023	12,014,569	(98,793)	11,915,776
Currency translation differences	-	1,007,692	1,007,692
<b>Other comprehensive income</b>	-	1,007,692	1,007,692
Transactions with owners in their capacity as owners:			
Issue of options	2,109,222	-	2,109,222
Exercise of options	1,178,002	-	1,178,002
Issue of convertible notes	19,090,797	-	19,090,797
Forfeiture of options	(319,550)	-	(319,550)
Provision for forfeiture payments	(101,486)	-	(101,486)
<b>At 31 December 2023</b>	<b>33,971,554</b>	<b>908,899</b>	<b>34,880,453</b>

**5 Equity (continued)****(b) Other reserves (continued)***a. Movement in options (share-based payment reserve)*

Details	Number of options
Balance at 1 July 2023	478,330,210
Exercise of listed options	741,935,748
Exercise of listed options IMUOE	(4,112,079)
Issue of ESOP unlisted options	146,540,279
Forfeiture of listed options	(8,000,400)
<b>Balance at 31 December 2023</b>	<b>1,354,693,758</b>

**(c) Other equity**

	31 December 2023 \$	30 June 2023 \$
Contingent issue of equity	4,744,355	4,744,355

Contingent issue of equity includes amounts related to the value of consideration shares to be issued to the previous Vaxinia Pty Ltd shareholders once certain milestones are met as per their agreement. For more information, please refer to note 7(b).

**6 Share-based payments****(a) Employee share option plan (ESOP)**

The assessed fair value of options at grant date was determined using the Black-Scholes option pricing model that takes into account the exercise price, term of the option, security price at grant date and expected price volatility of the underlying security, the expected dividend yield, the risk-free interest rate for the term of the security and certain probability assumptions.

The model inputs for options re-valued and granted under ESOP during the half-year 31 December 2023 included:

Grant date	Expiry date	Exercise Price (\$)	No. of options	Share price at grant date (\$)	Expected volatility	Dividend yield	Risk-free interest rate	Fair value at grant date (\$)
2023-09-01	2028-09-13	0.067	8,000,000	0.066	87.79%	0.00%	3.75%	392,001
2023-09-01	2028-09-13	0.067	10,000,000	0.066	87.79%	0.00%	3.75%	489,999
2023-08-14	2028-09-13	0.091	12,000,000	0.092	87.77%	0.00%	3.92%	768,000
			<b>30,000,000</b>					

**6 Share-based payments (continued)****(b) RSUs/Performance rights**

Grant date	Expiry date	Exercise Price (\$)	No. of rights	Share price at grant date (\$)	Expected volatility	Dividend yield	Risk-free interest rate	Fair value at grant date (\$)
15/08/2023	15/08/2030	-	5,699,317	0.094	87.35%	0.00%	3.94%	535,736
09/10/2023	9/10/2030	-	350,000	0.045	87.35%	0.00%	3.94%	15,750
16/10/2023	16/10/2030	-	75,000	0.044	87.35%	0.00%	3.94%	3,300
23/10/2023	23/10/2030	-	120,000	0.041	87.35%	0.00%	3.94%	4,920
06/11/2023	6/11/2030	-	75,000	0.066	87.35%	0.00%	3.94%	4,950
20/11/2023	20/11/2030	-	150,000	0.089	87.35%	0.00%	3.94%	13,350
27/11/2023	27/11/2030	-	100,000	0.091	87.35%	0.00%	3.94%	9,100
30/11/2023	30/11/2030	-	109,970,962	0.110	87.35%	0.00%	3.94%	11,871,041

Restricted Stock Units (RSUs) and Performance Rights vest on a combination of corporate goals and personal short-term incentive (STI) goals. An average annual risk of forfeiture has been assumed 0%.

**7 Contingent consideration****(a) PD-1 and Non PD-1 intellectual property**

The Group signed an exclusive licence with the Ohio State University and Mayo Clinic on 6 June 2018 to 16 issued patents or pending applications comprising PD-1 and Non PD-1 intellectual property. As a result, the Group has incurred liabilities contingent on future events in respect of each agreement (i.e. the separate PD-1 and Non PD-1 agreements):

- **Royalties on sales:** 3 percent of sales where annual turnover is less than US\$1 billion; 4 percent where annual turnover is greater than US\$1 billion
- **Milestone fees:** Up to US\$250,000 payable upon dosing of the first patient in each phase of a clinical trial; US\$1,000,000 payable upon first commercial sale
- **Annual licence fees:** US\$250,000 per annum payable contingent on first commercial sale
- **Sublicence fees:**
  - 25 percent of sublicensing consideration prior to first patient dosing in Phase I clinical trial
  - 15 percent of sublicensing consideration prior to first patient dosing in Phase II clinical trial
  - 10 percent of sublicensing consideration prior to first patient dosing in Phase III clinical trial
  - 8 percent of sublicensing consideration after first patient dosing in Phase III clinical trial

**(b) CF33 intellectual property**

The key financial terms of the purchase include a cash payment of \$97,588 and the issue of 127,994,355 shares in Imugene Limited. There is a deferred consideration element of three earnout components should certain milestones be achieved:

Milestone	Description	Consideration shares	Value
1.	Allowance of investigational new drug by the US Food and Drug Administration in relation to CF33	119,354,838	\$6,325,806
2.	Dosing of first patient in a Phase 1 clinical trial for CF33	134,258,064	\$7,115,677
3.	Meeting Phase 1 safety endpoints excluding efficacy and dose	149,193,548	\$7,907,258

## 7 Contingent consideration (continued)

### (b) CF33 intellectual property

At the end of the current reporting period, milestones 1 & 2 have been met and were settled in shares.

Also, in 2021, the Group separately signed the Exclusive License Agreement with the City of Hope (COH) to acquire a worldwide exclusive license to the promising oncolytic virus technology, known as CF33, developed at City of Hope, a world-renowned independent research and treatment centre for cancer, diabetes and other life-threatening diseases based in Los Angeles, California. The key financial terms of the purchase include a cash payment of US\$3 million, which was paid in 2021. The Group has also incurred liabilities contingent on future events in respect of the license, which are summarised below.

Development milestone payments: Up to US\$1.5m payable to the COH upon meeting various milestones:

Milest one	Deadline	Requirement	Payment to COH
1.	8 July 2021	To dose the first patient in a Phase 1 clinical trial of CF33	US\$0.15m
2.	8 July 2023	To dose the first patient in a Phase 2 clinical trial of CF33	US\$0.3m
3.	8 July 2026	To dose the first patient in a Phase 3 clinical trial of CF33	US\$1m
4.	8 July 2029	Receive marketing approval in the US for CF33	US\$3m
5.	No deadline	Receive marketing approval in any jurisdiction other than the US	US\$1.5m

In 2022, milestone 1 was met and was settled with a payment of cash.

#### Sales Milestone Payments:

Once the following Milestones have been met, the Group will have paid a total of US\$150 million. These milestones have no effect on the figures reported in the financial statements as at 31 December 2023 (June 2023: none).

- **Milestone 1:** Net sales first totalling US\$125 million.
- **Milestone 2:** Net sales first totalling US\$250 million.
- **Milestone 3:** Net sales first totalling US\$500 million.
- **Milestone 4:** Net sales first totalling US\$1 billion.

#### Royalties on net sales:

The Group is obliged to pay COH royalties on net sales based on industry standard single digit loyalty rates. This has no effect on the figures reported as at 31 December 2023 (30 June 2023: none).

### (c) CD19 intellectual property

In 2021, the Group signed the Exclusive License Agreement with COH to acquire a worldwide exclusive license to the promising CAR-T technology, known as CD19, developed at City of Hope, a world-renowned independent research and treatment centre for cancer, diabetes and other life-threatening diseases based in Los Angeles, California. The key financial terms of the purchase include a cash payment of US\$4 million, which was paid in 2022. The Group has also incurred liabilities contingent on future events in respect of the license, which are summarised below:

**7 Contingent consideration (continued)****(c) CD19 intellectual property (continued)**

**Development Milestone Payments:** Up to US\$6.55m payable to the COH upon meeting various milestones:

Milestone	Requirement	Payment to COH
1.	Upon the earlier of (a) initiation of cGMP manufacturing or (b) submission of a IND., in each case, for a Licensed Product expressing a target protein other than CD19, including expression of CD19 in conjunction with another target protein.	US\$1m
2.	Dosing of the first patient in the first Phase 1 Clinical Trial anywhere in the Territory.	US\$0.1m
3.	Dosing of the first patient in the first Phase 2 Clinical Trial anywhere in the Territory.	US\$0.2m
4.	Dosing of the first patient in the first Phase 3 Clinical Trial anywhere in the Territory.	US\$0.75m
5.	Upon the first Marketing Approval in the United States	US\$3m
6.	Upon the first Marketing Approval in any jurisdiction other than the United States.	US\$1.5m

At the end of the current reporting period, milestone 1 has been met and settlement is yet to be processed.

**Sales Milestone Payments:**

Once the following Milestones have been met, the Group will have paid a total of US\$115 million. These milestones have no effect on the figures reported in the financial statements as at 31 December 2023 (June 2023: none).

- **Milestone 1:** Net sales first totalling US\$125 million.
- **Milestone 2:** Net sales first totalling US\$250 million.
- **Milestone 3:** Net sales first totalling US\$500 million.
- **Milestone 4:** Net sales first totalling US\$1 billion.

**Royalties on net sales:**

The Group is obliged to pay COH royalties on net sales based on industry standard single digit royalty rates. This has no effect on the figures reported as at 31 December 2023 (30 June 2023: none).

**(d) Azer-cel intellectual property**

In the 16th of August 2023, the Group announced it had entered into an agreement with Precision Biosciences, Inc. to acquire an exclusive licence to azer-cel allogeneic CD19 CAR T cell therapy program. The key financial terms of the purchase include a cash payment of US\$8 million, which was paid in 2023, and deferred consideration of US\$13 million that has a term of 12 months and may be settled in cash or shares at the Group's discretion. The Group has also incurred liabilities contingent on future events in respect of the license, which are summarised below:



**7 Contingent consideration (continued)****(d) Azer-cel intellectual property (continued)**

**Regulatory and First Commercial Sale Milestones:** up to US\$86m payable to Precision Biosciences upon meeting various milestones:

Milestone	Requirement	Payment to Precision Biosciences
1.	Joint Steering Committee determination to proceed with a pivotal trial for an existing product	US\$8m
2.	First patient enrolled in a pivotal clinical trial	US\$10m
3.	First commercial sale of an existing product in the US for a first Indication	US\$10m
4.	First commercial sale of an existing product in the EU for a first indication	US\$10m
5.	First commercial sale of an existing product in the US for a second indication	US\$10m
6.	First commercial sale of an existing product in the EU for a second indication	US\$8m
7.	First commercial sale of an additional product in the US for a first indication	US\$10m
8.	First commercial sale of an additional product in the EU for a first indication	US\$8m
9.	First commercial sale of an additional product in the US for a second indication	US\$7m
10.	First commercial sale of an additional product in the EU for a second indication	US\$5m

At the end of the current reporting period, none of the above milestones have been met.

**Commercial Milestones:** up to US\$265m payable to Precision Biosciences upon meeting various milestones:

Milestone	Requirement	Payment to Precision Biosciences
1.	First calendar year in which annual aggregate global net sales of the existing product equals or exceed \$250,000,000	US\$20m
2.	First calendar year in which annual aggregate global net sales of the existing product equals or exceed \$500,000,000	US\$40m
3.	First calendar year in which annual aggregate global net sales of the existing product equals or exceed one billion dollars	US\$90m
4.	First calendar year in which annual aggregate global net sales of an additional product equals or exceed \$250,000,000	US\$15m
5.	First calendar year in which annual aggregate global net sales of an additional product equals or exceed \$500,000,000	US\$30m
6.	First calendar year in which annual aggregate global net sales of an additional product equals or exceed one billion dollars	US\$70m

At the end of the current reporting period, none of the above milestones have been met.

## 7 Contingent consideration (continued)

### (d) Azer-cel intellectual property (continued)

#### Royalties on Net Sales:

The group is obliged to pay COH royalties on net sales based on industry standard single digit royalty rates. This has no effect on the figures reported as at 31 December 2023 (30 June 2023: none).

### (e) Share arrangement

The Group agreed to granting Charles Walker \$300,000 worth of shares in the Group during the 2014 AGM for his services as Chief Executive Officer. Part of the agreement included that if or when he sold the shares, he would be required to repay Imugene the \$300,000. If a portion of shares were sold, he is required to pay a portion of the outstanding sum to the Group.

At 31 December 2023 \$22,168 (June 2023: \$114,000) of the original amount represents a contingent asset, while the remaining \$277,832 (June 2023: \$186,000) has been repaid to Imugene.

## 8 Commitments

### (a) Research and development commitments

The Group had research and development commitments at 31 December 2023 in respect of:

#### i. Arginine modulator intellectual property

On 13 December 2016, the Group announced it had entered into an agreement with Baker IDI Heart and Diabetes Institute Holdings Limited where a contingent liability exists relating to the commercialisation of arginine modulator intellectual property. As at 31 December 2023, no liability was recognised on the basis that commercialised income cannot be reliably measured.

#### ii. PD-1 and Non PD-1 intellectual property

The Group signed an exclusive licence with the Ohio State University and Mayo Clinic on 6 June 2018 to 16 issued patents or pending applications comprising PD-1 and Non PD-1 intellectual property. As a result, the Group has incurred the following commitments in respect of each agreement (i.e. the separate PD-1 and Non PD-1 agreements):

**Maintenance fees:** Up to US\$100,000 payable annually each anniversary of the agreement, until the date of first commercial sale.

#### iii. CF33 intellectual property

The Group had number of commitments in relation to the Agreement signed with City of Hope per the below:

Licensee Diligence: The Group is required to spend research and development commitments to develop CF33 in relation to the Agreement entered with the COH:

Milestone	Deadline	Requirement
1.	8 July 2021	To spend not less than US\$6m on the development of CF33
2.	8 July 2021	To dose the first patient in a Phase 1 clinical trial of CF33
3.	8 July 2023	To spend not less than US\$9m, in addition to the US\$6m spent for Milestone 1, on the development of CF33
4.	8 July 2023	To dose the first patient in a Phase 2 clinical trial of CF33
5.	8 July 2026	To dose the first patient in a Phase 3 clinical trial of CF33
6.	8 July 2029	Receive marketing approval in the US for CF33

**8 Commitments (continued)****(d) Research and development commitments (continued)**

At 31 December 2023, Milestones 1,2 and 3 have been completed with the remaining still outstanding. Phase 1 is still ongoing so Milestone 4 has no effect on the figures reported in the financial statements as at 31 December 2023 (June 2023: none).

**Licence maintenance fee:** Non-refundable annual licence fee is payable to COH of US\$50,000. Payment is required on or before 10th business day after the beginning of each license year (excluding first license year ending 31 December 2019).

iv. CD19 intellectual property

The Group had the following commitments in relation to the Agreement signed with City of Hope:

**Licence maintenance fee:** Non-refundable annual license fee is payable to City of Hope of US\$50,000. This is payable on or before the tenth business day after the beginning of each License Year (excluding the first licence year ending December 31, 2021).

**9 Events occurring after the reporting period**

In February 2024, milestone 3 for CF33 was met and settled in shares. This does not require an adjustment to the financial statements.

**10 Loss per share****(a) Reconciliation of earnings used in calculating loss per share**

	Consolidated entity	
	31 December 2023	31 December 2022
	\$	\$
<i>Basic and diluted loss per share</i>		
Loss attributable to the ordinary equity holders of the Group used in calculating loss per share:		
From continuing operations	(68,714,834)	(17,392,700)
From discontinued operations	-	-
	<u>(68,714,834)</u>	<u>(17,392,700)</u>

**(b) Reconciliation of earnings used in calculating loss per share**

	Consolidated entity	
	31 December 2023	31 December 2022
	\$	\$
Weighted average number of ordinary shares used as the denominator in calculating basic and diluted loss per share	6,882,004,092	6,132,016,636

The outstanding options as at 31 December 2023 are considered to be anti-dilutive and therefore were excluded from the diluted weighted average number of ordinary shares calculation.

## 11 Basis of preparation of interim report

These condensed consolidated financial statements for the half-year reporting period ended 31 December 2023 have been prepared in accordance with accounting standard AASB 134 *Interim Financial Reporting* and the Corporations Act 2001. These financial statements also comply with International Financial Reporting Standards (IFRS) as issued by the International Accounting Standards Board (IASB).

These condensed consolidated financial statements do not include all the notes of the type normally included in an annual financial report. Accordingly, this report is to be read in conjunction with the annual report for the year ended 30 June 2023 and any public announcements made by Imugene Limited during the interim reporting period in accordance with the continuous disclosure requirements of the Corporations Act 2001 and ASX Listing Rules.

The accounting policies adopted are consistent with those of the previous financial year and corresponding interim reporting period.

Significant judgements, estimates and assumptions made by management in the preparation of the interim report, including the key sources of estimation uncertainty, are updated for the reporting date and consistent with those applied in annual report for the year ended 30 June 2023.

On 15 August 2023, the Group acquired the worldwide exclusive license to azer-cel, an allogeneic CD19 CAR T cell therapy program. Given the nature of the transaction, it has been concluded that this is an asset acquisition for the purchase of property, plant and equipment, leases, intangible assets, other financial liabilities and other current assets for a total consideration of US\$21,300,000. The cost incurred has been allocated to the individual identifiable assets and liabilities based on their relative fair values at the date of purchase.

Except for the accounting treatment of azer-cel above, there have been no material changes to the critical judgements made or the basis of estimation for significant estimates between the previous annual report and this interim report. Changes in estimated amounts arise from changes in performance rather than changes in the basis of estimation, as shown in the relevant notes to this interim report.

## Directors' declaration

In the directors' opinion:

- (a) the financial statements and notes set out on pages 11 to 27 are in accordance with the Corporations Act 2001, including:
  - (i) complying with AASB 134 *Interim Financial Reporting*, the Corporations Regulations 2001 and other mandatory professional reporting requirements, and
  - (ii) giving a true and fair view of the consolidated entity's financial position as at 31 December 2023 and of its performance for the half-year ended on that date, and
- (b) there are reasonable grounds to believe that the Group will be able to pay its debts as and when they become due and payable.

This declaration is made in accordance with a resolution of directors.



Mr Paul Hopper  
Executive Chairman

Sydney  
29 February 2024

**Grant Thornton Audit Pty Ltd**

Level 22 Tower 5  
Collins Square  
727 Collins Street  
Melbourne VIC 3008  
GPO Box 4736  
Melbourne VIC 3001  
T +61 3 8320 2222

## Independent Auditor's Review Report

### To the Members of Imugene Limited

#### Report on the half year financial report

##### Conclusion

We have reviewed the accompanying half year financial report of Imugene Limited (the Company) and its subsidiaries (the Group), which comprises the consolidated statement of financial position as at 31 December 2023, and the consolidated statement of profit or loss and other comprehensive income, consolidated statement of changes in equity and consolidated statement of cash flows for the half year ended on that date, a summary of significant accounting policies, other selected explanatory notes, and the directors' declaration.

Based on our review, which is not an audit, we have not become aware of any matter that makes us believe that the accompanying half-year financial report of Imugene Limited does not comply with the *Corporations Act 2001* including:

- a giving a true and fair view of the Group's financial position as at 31 December 2023 and of its performance for the half year ended on that date; and
- b complying with Accounting Standard AASB 134 *Interim Financial Reporting and the Corporations Regulations 2001*.

##### Basis for Conclusion

We conducted our review in accordance with ASRE 2410 *Review of a Financial Report Performed by the Independent Auditor of the Entity*. Our responsibilities are further described in the Auditor's Responsibilities for the Review of the Financial Report section of our report. We are independent of the Company in accordance with the auditor independence requirements of the *Corporations Act 2001* and the ethical requirements of the Accounting Professional and Ethical Standards Board's APES 110 *Code of Ethics for Professional Accountants (including Independence Standards)* (the Code) that are relevant to our audit of the annual financial report in Australia. We have also fulfilled our other ethical responsibilities in accordance with the Code.

[www.grantthornton.com.au](http://www.grantthornton.com.au)  
ACN-130 913 594

Grant Thornton Audit Pty Ltd ACN 130 913 594 a subsidiary or related entity of Grant Thornton Australia Limited ABN 41 127 556 389 ACN 127 556 389. 'Grant Thornton' refers to the brand under which the Grant Thornton member firms provide assurance, tax and advisory services to their clients and/or refers to one or more member firms, as the context requires. Grant Thornton Australia Limited is a member firm of Grant Thornton International Ltd (GTIL). GTIL and the member firms are not a worldwide partnership. GTIL and each member firm is a separate legal entity. Services are delivered by the member firms. GTIL does not provide services to clients. GTIL and its member firms are not agents of, and do not obligate one another and are not liable for one another's acts or omissions. In the Australian context only, the use of the term 'Grant Thornton' may refer to Grant Thornton Australia Limited ABN 41 127 556 389 ACN 127 556 389 and its Australian subsidiaries and related entities. Liability limited by a scheme approved under Professional Standards Legislation.

### Directors' responsibility for the half-year financial report

The Directors of the Company are responsible for the preparation of the half-year financial report that gives a true and fair view in accordance with Australian Accounting Standards and the *Corporations Act 2001* and for such internal control as the Directors determine is necessary to enable the preparation of the half-year financial report that gives a true and fair view and is free from material misstatement, whether due to fraud or error.

### Auditor's responsibility

Our responsibility is to express a conclusion on the half-year financial report based on our review. We conducted our review in accordance with Auditing Standard on Review Engagements ASRE 2410 *Review of a Financial Report Performed by the Independent Auditor of the Entity*, in order to state whether, on the basis of the procedures described, we have become aware of any matter that makes us believe that the half year financial report is not in accordance with the *Corporations Act 2001* including giving a true and fair view of the Group's financial position as at 31 December 2023 and its performance for the half-year ended on that date, and complying with Accounting Standard AASB 134 *Interim Financial Reporting and the Corporations Regulations 2001*.

A review of a half-year financial report consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Australian Auditing Standards and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Grant Thornton Audit Pty Ltd  
Chartered Accountants

M A Cunningham  
Partner – Audit & Assurance

Melbourne, 29 February 2024



**IMUGENE**

Developing Cancer  
Immunotherapies

ASX:IMU

**Contact**



**info@imugene.com**  
**imugene.com**

For personal use only